Last reviewed · How we verify
Transfusion of blood products
Transfusion of blood products is a Blood product transfusion Biologic drug developed by Fundacion Clinica Valle del Lili. It is currently FDA-approved for Acute hemorrhage and hypovolemic shock, Severe anemia, Thrombocytopenia or platelet dysfunction.
Transfusion of blood products restores circulating blood volume, oxygen-carrying capacity, and clotting factors to treat hemorrhage, anemia, or coagulopathy.
Transfusion of blood products restores circulating blood volume, oxygen-carrying capacity, and clotting factors to treat hemorrhage, anemia, or coagulopathy. Used for Acute hemorrhage and hypovolemic shock, Severe anemia, Thrombocytopenia or platelet dysfunction.
At a glance
| Generic name | Transfusion of blood products |
|---|---|
| Sponsor | Fundacion Clinica Valle del Lili |
| Drug class | Blood product transfusion |
| Modality | Biologic |
| Therapeutic area | Hematology/Critical Care |
| Phase | FDA-approved |
Mechanism of action
Blood product transfusion replaces lost or deficient blood components including red blood cells (oxygen transport), platelets (hemostasis), plasma (coagulation factors), and whole blood. This restores hemodynamic stability, tissue oxygenation, and hemostatic function in patients with acute blood loss, chronic anemia, or acquired or congenital coagulation disorders.
Approved indications
- Acute hemorrhage and hypovolemic shock
- Severe anemia
- Thrombocytopenia or platelet dysfunction
- Coagulopathy and clotting factor deficiency
Common side effects
- Transfusion reaction (acute hemolytic)
- Febrile non-hemolytic transfusion reaction
- Allergic reaction
- Transfusion-related acute lung injury (TRALI)
- Infection (bacterial, viral)
- Iron overload (with chronic transfusion)
- Alloimmunization
Key clinical trials
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients (NA)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Comparison of Efficacy and Safety of Manual Syringing Versus Pneumatic Pressure Bag for Blood Transfusion in Patients Undergoing Cesarean Section With Major Obstetric Hemorrhage (NA)
- Thrombelastometry-guided Blood Component Administration Versus Standard of Care in Patients With Decompensated Liver Cirrhosis Undergoing Invasive Procedures (NA)
- Siplizumab for Sickle Cell Disease Transplant (PHASE1, PHASE2)
- Bleeding Management İn Open Heart Surgery (NA)
- Evaluation of a Transfusion Therapy Using Whole Blood in the Management of Coagulopathy in Patients With Acute Traumatic Hemorrhage (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transfusion of blood products CI brief — competitive landscape report
- Transfusion of blood products updates RSS · CI watch RSS
- Fundacion Clinica Valle del Lili portfolio CI
Frequently asked questions about Transfusion of blood products
What is Transfusion of blood products?
How does Transfusion of blood products work?
What is Transfusion of blood products used for?
Who makes Transfusion of blood products?
What drug class is Transfusion of blood products in?
What development phase is Transfusion of blood products in?
What are the side effects of Transfusion of blood products?
Related
- Drug class: All Blood product transfusion drugs
- Manufacturer: Fundacion Clinica Valle del Lili — full pipeline
- Therapeutic area: All drugs in Hematology/Critical Care
- Indication: Drugs for Acute hemorrhage and hypovolemic shock
- Indication: Drugs for Severe anemia
- Indication: Drugs for Thrombocytopenia or platelet dysfunction
- Compare: Transfusion of blood products vs similar drugs
- Pricing: Transfusion of blood products cost, discount & access